Clinical trial
A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
NCT00718523 is registered in ClinicalTrials.gov with Translational Research in Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo Controlled, Multi-center, Phase II Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) to First Line Chemotherapy in Patients With Optimally Debulked ( < 1 cm ) Epithelial Ovarian Cancer
- Lead sponsor
- Translational Research in Oncology
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 31, 2009
- Completion date
- November 30, 2014
- Enrollment
- 170 (actual)
- Sites
- 55
Conditions
As the registry lists them; a condition with its own page is linked.